A negative result might offer real peace of mind
In a Boston laboratory, researchers have uncovered a way to listen to the brain's earliest distress signals not through imaging or memory tests, but through the blood itself — years before the mind begins to falter or any scan reveals a trace of disease. Scientists at Mass General Brigham have shown that measuring a protein called phosphorylated tau 217 can detect the slow advance of Alzheimer's earlier than any tool previously available, quietly reordering the timeline between invisibility and diagnosis. The discovery does not yet change what doctors will tell their patients tomorrow, but it shifts something fundamental: the moment at which the future becomes knowable.
- A blood protein called pTau217 is detecting Alzheimer's disease in motion years before PET scans — long considered the earliest possible warning — can see anything at all.
- A study tracking 317 cognitively healthy adults over eight years found that elevated pTau217 levels predicted faster disease progression even when brain imaging appeared completely normal.
- Participants with low pTau217 levels showed strong likelihood of remaining amyloid-free for years, suggesting the test could offer genuine reassurance alongside risk identification.
- The FDA approved the first Alzheimer's blood test last year, and this research accelerates pressure to move biomarker screening from the lab into clinical trials and eventually routine care.
- Researchers are urging caution — widespread screening is not yet recommended — but the test's potential to replace expensive PET scans and identify prevention trial candidates is drawing serious attention.
In a Boston laboratory, scientists at Mass General Brigham have found that a simple blood test measuring a protein called phosphorylated tau 217 — pTau217 — can signal the onset of Alzheimer's years before a person notices anything wrong, and years before telltale plaques appear on brain imaging. For decades, PET scans were considered the earliest available warning, capable of revealing amyloid buildup a decade or two before symptoms emerged. This research suggests the blood test catches something earlier still.
The study followed 317 cognitively healthy adults between the ages of 50 and 90 for an average of eight years, tracking blood protein levels, brain scans, and cognitive change over time. People with higher pTau217 levels at the outset developed Alzheimer's pathology faster — even when their initial scans looked clean. Increases in pTau217 frequently appeared before PET scans turned positive, suggesting the blood was carrying news the brain had not yet made visible.
There was reassurance in the data as well. Participants who began the study with low pTau217 levels were very unlikely to accumulate significant amyloid-beta over the years that followed — a meaningful finding for those seeking clarity about their cognitive future. "Those with low pTau217 levels are likely to stay amyloid-negative for several years," said Hyun-Sik Yang, the neurologist who led the research at the Broad Institute of MIT and Harvard.
The discovery arrives as the field is already in motion. The FDA approved the first Alzheimer's blood test last year, opening the door to cheaper, less invasive alternatives to lumbar punctures and costly PET scans. This new research deepens that shift, demonstrating that blood biomarkers can detect the earliest whispers of disease before the brain itself shows visible change.
Still, the researchers urge patience. They are not yet recommending pTau217 testing for all older adults in routine care. The nearer horizon is clinical trials — using the test to identify people most likely to benefit from prevention drugs. Further out, as the science matures, biomarker screening could become part of standard health checkups, offering a more accessible window into cognitive risk than brain imaging has ever provided.
In a Boston laboratory, researchers have found something that might change how we catch Alzheimer's disease—not in the brain scans or the memory tests, but in the blood itself. Scientists at Mass General Brigham discovered that a simple blood test measuring a protein called phosphorylated tau 217, or pTau217, can signal the onset of Alzheimer's years before a person notices anything wrong, years even before the telltale plaques show up on brain imaging.
The finding matters because it pushes back the moment of detection. For decades, neurologists thought PET scans—expensive, time-consuming imaging studies—represented the earliest warning sign, revealing amyloid buildup in the brain a decade or two before symptoms emerged. But this new work suggests the blood test catches something earlier still. "We are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans," said Hyun-Sik Yang, the neurologist who led the research and works at the Broad Institute of MIT and Harvard.
The study followed 317 cognitively healthy older adults—people between 50 and 90 with no signs of cognitive trouble—for an average of eight years. Researchers drew blood to measure pTau217 levels, performed repeated brain scans, and tracked how their thinking changed over time. What they found was striking: people with higher pTau217 levels at the start developed Alzheimer's pathology faster, even when their initial scans looked clean. More tellingly, increases in pTau217 often appeared before the PET scans turned positive, suggesting the blood test was catching the disease in motion before imaging could see it.
There was also reassuring news for those with low pTau217 levels. Participants who started the study with minimal amounts of this protein were very unlikely to accumulate significant amyloid-beta over the years of follow-up—a sign that a negative result might offer real peace of mind. "Those with low pTau217 levels are likely to stay amyloid-negative for several years," Yang noted. The implication is clear: the blood test could identify who is truly at risk and who probably is not.
The timing of this discovery is significant. Last year, the FDA approved the first blood test for Alzheimer's, opening the door to cheaper, less invasive alternatives to lumbar punctures and the expensive PET scans that have long been the gold standard. This new research adds weight to that shift, showing that blood biomarkers can do something imaging cannot—detect the earliest whispers of disease before the brain itself shows visible change.
Yet the researchers are cautious about moving too fast. Yang and his colleagues say it is too early to recommend pTau217 testing for all older adults in routine medical care. What they do see is potential: the test could become a screening tool for clinical trials testing Alzheimer's prevention drugs, helping researchers find people most likely to benefit. Eventually, as the science solidifies, biomarker blood tests might become part of regular health checkups, offering a more affordable way to assess risk than brain imaging ever could.
The field is moving quickly. What begins as a research finding in a Boston lab could reshape how millions of people learn about their cognitive future—not through a scan or a symptom, but through a vial of blood and a number that tells a story years before the story becomes visible.
Notable Quotes
We are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans— Hyun-Sik Yang, neurologist at Mass General Brigham
By anticipating who's going to turn amyloid-positive in the future, we are trying to push back the clock to enable earlier Alzheimer's disease prediction— Jasmeer Chhatwal, co-senior author and neurologist at Mass General Brigham
The Hearth Conversation Another angle on the story
Why does it matter that we can detect this protein years before symptoms? Can we actually do anything about it?
That's the crucial question. Right now, we can't promise a cure. But if you know someone is on the path to Alzheimer's a decade early, you have time to enroll them in prevention trials, to test drugs that might slow or stop the process. That window matters enormously.
So this test is really a tool for research, not yet for patients.
Exactly. The researchers are being honest about that. They're not saying go get this blood test tomorrow. They're saying this could become the way we identify people for prevention studies—and eventually, if prevention drugs work, it becomes a tool for everyone.
What makes pTau217 special compared to other biomarkers?
It appears to catch the disease earlier than anything else we have. The brain scans that used to be our earliest warning sign? This protein shows up years before those scans light up. It's like the difference between seeing smoke and seeing fire.
If someone gets this test and it's negative, what does that mean?
It's genuinely reassuring. The study showed that people with low levels at the start stayed that way for years. A negative result suggests you're probably not on the Alzheimer's path, at least not yet.
What's the catch? Why aren't we doing this for everyone right now?
Cost, validation, and ethics. We need to know more about what a positive result means for an individual person. We need bigger studies. And we need to make sure we're not creating a class of people labeled as future Alzheimer's patients when we can't yet offer them a cure.